Quarry LP Has $188,000 Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Quarry LP lifted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 56.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,000 shares of the company’s stock after purchasing an additional 1,800 shares during the quarter. Quarry LP’s holdings in SpringWorks Therapeutics were worth $188,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of SWTX. Principal Financial Group Inc. boosted its position in shares of SpringWorks Therapeutics by 8.3% during the 4th quarter. Principal Financial Group Inc. now owns 16,120 shares of the company’s stock worth $588,000 after acquiring an additional 1,231 shares in the last quarter. Norges Bank acquired a new stake in shares of SpringWorks Therapeutics in the 4th quarter valued at $12,331,000. TD Asset Management Inc increased its stake in shares of SpringWorks Therapeutics by 30.7% in the 4th quarter. TD Asset Management Inc now owns 181,432 shares of the company’s stock valued at $6,622,000 after purchasing an additional 42,600 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of SpringWorks Therapeutics during the 4th quarter worth $486,000. Finally, Affinity Asset Advisors LLC lifted its position in shares of SpringWorks Therapeutics by 140.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 100,000 shares of the company’s stock worth $3,650,000 after buying an additional 58,419 shares during the last quarter.

Analyst Ratings Changes

SWTX has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and set a $76.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Finally, Wedbush reissued an “outperform” rating and set a $77.00 price objective (up previously from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $68.50.

SpringWorks Therapeutics Stock Performance

SWTX stock opened at $32.04 on Tuesday. The firm has a 50 day moving average of $37.01 and a 200-day moving average of $40.48. SpringWorks Therapeutics, Inc. has a 12 month low of $18.00 and a 12 month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to the consensus estimate of $34.42 million. During the same period in the previous year, the company posted ($1.25) EPS. The company’s revenue for the quarter was up 59732900.0% compared to the same quarter last year. On average, analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current fiscal year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.